October 29, 2024
SAN ANTONIO — The upcoming Obesity Week meeting will feature new clinical trial data for glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, along with deep […]
October 28, 2024
The US Food and Drug Administration (FDA) has notified compounding pharmacies that the agency — at least temporarily — won’t take action against them for creating […]
October 28, 2024
The potential of glucagon-like peptide 1 (GLP-1) receptor agonists continues to grow more promising as new studies identify benefits beyond glucose control and weight loss. With […]
October 25, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals to warn patients about common and serious side effects associated with glucagon-like peptide-1 receptor […]
October 25, 2024
TOPLINE: High-intensity exercise suppresses ghrelin levels more than moderate-intensity exercise, leading to a greater reduction in hunger. This effect may be more pronounced in women than […]
October 24, 2024
TOPLINE: Increases in prescriptions for both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors were observed in patients with type 1 […]
October 24, 2024
TOPLINE: A 48-week oral semaglutide treatment regimen for type 2 diabetes (T2D) reduces weight and improves liver steatosis, liver stiffness, and liver enzyme levels in patients […]
October 23, 2024
Eating a low-carbohydrate diet can help preserve beta-cell function in people with mild type 2 diabetes (T2D), potentially allowing some to achieve target glucose levels without […]
October 23, 2024
NEW YORK (Reuters) – Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health […]